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Summary 
 
Mechanistic target of rapamycin (mTOR) is a fundamental regulator of cell growth, 
proliferation and metabolism. mTOR is activated in renal cancer and accelerates 
tumor progression. Here, we report that the mTOR inhibitor, DEP domain-containing 
mTOR-interacting protein (DEPTOR) is strikingly suppressed in clear cell renal cell 
carcinoma (ccRCC) tumors and cell lines. We demonstrate that DEPTOR is 
repressed by both hypoxia-inducible factors, HIF-1 and HIF-2, which occurs through 
activation of the HIF-target gene and transcriptional repressor, 
BHLHe40/DEC1/Stra13. Restoration of DEPTOR and CRISPR/Cas9 mediated 
knockout experiments demonstrate that DEPTOR is growth inhibitory in ccRCC. 
Furthermore, loss of DEPTOR confers resistance to second generation mTOR 
kinase inhibitors through deregulated mTORC1 feedback to IRS-2/PI3K/Akt. This 
work reveals a hitherto unknown mechanism of resistance to mTOR kinase targeted 
therapy that is mediated by HIF-dependent reprograming of mTOR/DEPTOR 
networks and suggests that restoration of DEPTOR in ccRCC will confer sensitivity 
to mTOR kinase therapeutics. 
 
 
 
 
  
3 
 
Introduction 
Mechanistic target of rapamycin (mTOR) is a Ser/Thr protein kinase belonging to the 
phosphoinositide-3-kinase-related kinase (PIKK) family that regulates diverse cellular 
processes including cell growth, metabolism, and survival in response to nutrient and 
growth factor cues (Saxton and Sabatini, 2017). mTOR is part of two functionally 
distinct protein complexes, mTORC1 and mTORC2 which have multiple 
components, but are primarily characterized by addition of the accessory proteins, 
regulatory-associated protein of mTOR (Raptor) and rapamycin-insensitive 
companion of mTOR (Rictor) for mTORC1 and mTORC2, respectively (Saxton and 
Sabatini, 2017). Both complexes contain an inhibitory subunit, DEP domain-
containing mTOR-interacting protein (DEPTOR) (Caron et al., 2018; Peterson et al., 
2009). The expression of DEPTOR is tightly controlled and dependent on growth 
factor signals which suppress DEPTOR levels transcriptionally and by 
posttranslational modification (Peterson et al., 2009). Mitogenic signals lead to rapid 
DEPTOR phosphorylation on multiple sites, some of which are dependent on mTOR 
activity, and DEPTOR is subsequently targeted for proteasomal degradation by 
SCFβTrCP E3 ubiquitin ligase (Duan et al., 2011; Gao et al., 2011; Zhao et al., 2011). 
Therefore, mTOR and DEPTOR work in a reciprocal manner, each negatively 
regulating the expression of the other, depending on growth factor cues and nutrient 
status. Further work has demonstrated that DEPTOR is critical in maintaining 
mTORC1 homeostasis by regulating mTORC1 negative feedback signaling to insulin 
receptor substrate 1 (IRS-1) (Caron et al., 2017; Laplante et al., 2012; Peterson et 
al., 2009). 
Increased mTOR pathway activity is frequently observed in cancers with either 
mutations found in MTOR (Grabiner et al., 2014) or components of the PI3K/Akt 
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signaling pathway (Zhang et al., 2017). In clear cell renal cell carcinoma (ccRCC), 
which is the most common type of kidney cancer, mTORC1 pathway is commonly 
activated in vivo (Pantuck et al., 2007). As such, allosteric mTORC1 inhibitors are 
approved therapeutic agents as second-line therapy following anti-angiogenic 
therapy. However, second generation mTOR kinase inhibitors and dual 
PI3K/Akt/mTOR targeted therapies have failed to work in ccRCC as expected; the 
reasons for this are unclear (Powles et al., 2016a; Powles et al., 2016b). The 
majority of ccRCC tumors are characterized by inactivation of the von Hippel-Lindau 
tumor suppressor protein (pVHL), which is part of an E3 ligase complex (Shen and 
Kaelin, 2013). Defective pVHL leads to stabilization of hypoxia-inducible factors, HIF-
1α and HIF-2α, that regulate transcription of numerous genes involved in cell 
proliferation, angiogenesis and metabolism (Shen and Kaelin, 2013). Multiple lines of 
evidence have demonstrated that the HIF-2α subunit is the tumor promoting isoform 
in ccRCC (Shen and Kaelin, 2013). Since existing anti-angiogenic and mTOR-
targeted therapies provide only short-term benefit, specific HIF-2 inhibitors have 
been developed and are in clinical trials (Chen et al., 2016; Cho et al., 2016; Wallace 
et al., 2016). 
One puzzle in ccRCC, is that neither mutations in components of PI3K/Akt/mTOR 
pathway, nor current understanding of mTOR/HIF signaling, can account for all of 
the elevated mTOR pathway activity found in ccRCC (Kucejova et al., 2011; Zhang 
et al., 2017). HIF is generally thought to inhibit mTOR by activation of regulated in 
development and DNA damage response 1 (REDD1) gene (Brugarolas et al., 2004). 
However, mTOR can evade HIF/REDD1 negative regulation in a cell line dependent 
manner (Kucejova et al., 2011). This suggests there must be other mechanisms of 
activation of mTOR in ccRCC (Elorza et al., 2012) and/or negative regulators of the 
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pathway are suppressed. DEPTOR is found in low levels in many, but not all cancers 
(Peterson et al., 2009). However, little is known about the role of DEPTOR in 
ccRCC. Here, we show that DEPTOR is suppressed in pVHL-inactivated ccRCC in a 
HIF-dependent manner. DEPTOR suppression accelerates proliferation of ccRCC 
cells and promotes resistance to second generation mTOR kinase inhibitors as 
compensatory activation of Akt is suppressed when DEPTOR is downregulated. Our 
work reveals important new mechanistic insight into deregulation of mTOR in ccRCC 
that is mediated by HIF reprogramming of mTOR/DEPTOR signaling.  
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Results 
DEPTOR is suppressed in VHL-deficient ccRCC 
mTOR activity is increased in pVHL-deficient ccRCC and is a therapeutic target, but 
little is known about the expression of its endogenous inhibitor, DEPTOR. Microarray 
expression analysis using the Beroukhim renal cancer data set (Beroukhim et al., 
2009) demonstrated a significant decrease in DEPTOR mRNA in both hereditary and 
spontaneous VHL-deficient ccRCC tumor samples as compared with normal renal 
cortex (Fig 1A). Another cohort of matched ccRCC tumors and normal cortex (Gumz 
et al., 2007) also revealed a significant decrease in DEPTOR mRNA in 8 out of 10 
samples (Fig 1B). In addition, DEPTOR mRNA and protein were strikingly 
suppressed in VHL-deficient ccRCC cells (786-O, RCC4) as compared with cells 
transfected with VHL (786-O/VHL and RCC4/VHL) as shown in Fig 1C and 1D. 
These results demonstrate that DEPTOR is significantly downregulated in ccRCC 
tumors and cell lines in a VHL-dependent manner. 
 
DEPTOR is suppressed by HIFs in VHL-deficient ccRCC 
Genetic alterations in PI3K/Akt/mTOR pathway components are important 
contributors to mTOR activation in renal cancer (Brugarolas, 2014). However, 
mutations in PI3K/Akt/mTOR proteins do not account for the widespread increase in 
mTOR pathway activity found in tumors (Zhang et al., 2017). We performed an 
analysis of Deptor genetic alterations from the Cancer Genome Atlas (TCGA) 
database which revealed genetic alterations in only 5 of 499 cases (1%; 4 
amplifications and 1 missense mutation) which suggests that other mechanisms 
contribute to suppression of DEPTOR in ccRCC. Studies investigating the regulation 
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of DEPTOR have shown it to be tightly regulated by posttranslational modification 
(Duan et al., 2011; Gao et al., 2011; Peterson et al., 2009; Zhao et al., 2011). Upon 
serum or mitogen activation, DEPTOR is rapidly phosphorylated in an mTOR-
dependent manner and targeted for degradation by SCFβTrCP E3 ligase (Duan et al., 
2011; Gao et al., 2011; Zhao et al., 2011). Therefore, increased mTOR activity can 
promote DEPTOR degradation. To test whether mTOR contributed to DEPTOR 
suppression, ccRCC cells were incubated with an ATP-competitive mTOR kinase 
inhibitor, AZD2014 (Fig 2A). As expected, AZD2014 decreased phosphorylation of 
mTORC1 and mTORC2 substrates, S6K1 and Akt respectively, in both VHL-
deficient and VHL-competent cells. mTOR kinase ablation increased DEPTOR 
protein accumulation in VHL-expressing cells only (786-O/VHL and RCC4/VHL), as 
previously shown in other cell types that are also VHL wild-type (Peterson et al., 
2009), indicating that mTOR activity was not responsible for the low levels of 
DEPTOR observed in VHL-deficient cells (786-O and RCC4). In addition, DEPTOR 
is suppressed at the level of transcript (Fig 1C and Supplementary Fig 1A), and 
mRNA levels were not affected by AZD2014, suggesting that DEPTOR is 
suppressed by transcriptional or post-transcriptional mechanisms. This was 
supported by results showing that addition of the proteasome inhibitor, MG132, had 
no effect on DEPTOR protein levels in VHL-deficient 786-O cells (Supplementary Fig 
1B), supporting the suggestion that DEPTOR is not supressed by posttranslational 
mechanisms in VHL-deficient renal cells.  
 
Loss of pVHL leads to stabilization of the transcription factors HIF-1α and HIF-2α, 
due to defective pVHL-mediated degradation of HIF-α subunits (Maxwell et al., 
1999). Since numerous studies have identified the importance of HIF-2α in ccRCC 
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(Shen and Kaelin, 2013), the isoform specific HIF-2 antagonist PT2385, which 
prevents HIF-2α from binding to ARNT/HIF-1β, was used to inhibit HIF-2 
transcriptional activity (Chen et al., 2016; Wallace et al., 2016). Inhibition of HIF-2 
activity by PT2385 was confirmed by measurement of HIF-2 specific target genes, 
vascular endothelial growth factor (VEGF), endothelin-1 (ET-1) and plasminogen 
activator inhibitor-1 (PAI-1), which were all significantly down regulated; 
demonstrating the expected effect of HIF-2 inhibition (Supplementary Fig 1C). 
PT2385 treatment of both 786-O and RCC4 cells resulted in a marked increase in 
DEPTOR mRNA and protein (Fig 2B and 2C). PT2385 also inhibited HIF-2α protein 
accumulation, which has been noted previously (Cho et al., 2016; Wallace et al., 
2016). To test whether HIF-1α was also able to inhibit DEPTOR, the effects of HIF-
1α and HIF-2α ablation were investigated by siRNA-mediated knockdown (Fig 2D 
and 2E). Downregulation of HIFs was confirmed by RT-PCR (Supplementary Fig 
1D). Both HIF-1α and HIF-2α inhibition increased DEPTOR mRNA and protein 
indicating that DEPTOR is suppressed by both HIFs in ccRCC (Fig 2D and 2E). To 
determine whether DEPTOR is also suppressed by hypoxia in VHL competent cells, 
RCC4/VHL and 786-O/VHL cells were exposed to low oxygen tension. Hypoxia 
induced DEPTOR downregulation in RCC4/VHL (Fig 2F and Supplementary Fig 2A) 
and 786-O/VHL cells (Supplementary Fig 2B) in a time-dependant manner. This 
occurred with a concomitant stabilization of HIF-2α, indicating that DEPTOR is also 
repressed in cells with functional oxygen-sensing machinery. Together, these results 
demonstrate that DEPTOR is suppressed in a HIF-dependent manner in ccRCC.  
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HIF-dependent downregulation of DEPTOR is mediated by BHLHe40 
Previous work has demonstrated that HIFs do not function as transcriptional 
repressors of cognate target genes (Schödel et al., 2011), but act by induction of 
transcriptional intermediates (Evans et al., 2007; LaGory et al., 2015), or by 
posttranscriptional mechanisms such as induction of hypoxia-inducible microRNAs 
(miRNAs) (Choudhry and Mole, 2016). We investigated expression of known HIF-
dependent transcriptional repressors, zinc finger protein SNAI1 (Snail) (Evans et al., 
2007) and basic-helix-loop-helix family member e40 (BHLHe40) (LaGory et al., 
2015). BHLHe40 is alternatively known as DEC1/Stra13/SHARP2 (Kato et al., 2014). 
Both Snail and BHLHe40 were upregulated in ccRCC tumors as compared with 
matched normal renal cortex as expected in the Gumz data set (Gumz et al., 2007) 
(Fig 3A and 3B). Snail did not correlate significantly with DEPTOR expression (Fig 
3C), but a significant inverse correlation of DEPTOR was found with BHLHe40 in the 
combined data set of normal kidney and ccRCC tumors (n=20) (Fig 3D). 
Furthermore, DEPTOR levels strongly positively correlated with peroxisome 
proliferator-activated receptor-γ coactivator (PGC-1α) (Fig 3E), a gene which has 
previously been shown to be repressed by BHLHe40 in ccRCC (LaGory et al., 2015), 
suggesting a common mechanism of repression. To explore the role of BHLHe40 in 
DEPTOR regulation further, mRNA and protein levels were determined in renal cells. 
BHLHe40 was upregulated in 786-O and RCC4 cells as compared with VHL 
competent cells and correlated with HIF-2α as expected (Fig 3F and Supplementary 
Fig 2C). Re-expression of VHL resulted in diminished HIF-2α and BHLHe40 
accumulation together with a concomitant increase in DEPTOR levels (Fig 3F). 
BHLHe40 transcript increased in a time-dependent manner in hypoxia in VHL 
competent cells with functional oxygen sensing machinery (Fig 3G and 
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Supplementary Fig 2D), that corresponded with a reduction in DEPTOR (Fig 3G and 
Supplementary Fig 2B). We also confirmed BHLHe40 expression was dependent on 
HIF-2α, since it was markedly reduced by the HIF-2 inhibitor, PT2385 (Fig 3H). 
Finally, to confirm the role of BHLHe40 on DEPTOR suppression, VHL-deficient cells 
were treated with BHLHe40 siRNA. Inhibition of BHLHe40 led to increased DEPTOR 
accumulation in 786-O and RCC4 VHL-deficient cells (Fig 3I). Together, these 
results demonstrate that HIF-mediated repression of DEPTOR occurs through 
BHLHe40. 
 
HIF inhibition increases DEPTOR accumulation and attenuates mTOR 
phosphorylation at S2448 
mTOR controls synthesis of HIF-α subunits (Toschi et al., 2008) and HIFs, in turn, 
have been shown to suppress mTOR activity in a negative feedback loop, likely 
mediated by the HIF target gene REDD1 (Brugarolas et al., 2004; Kucejova et al., 
2011). However, in ccRCC, where HIFs are overexpressed, mTOR is hyperactive 
and has been demonstrated to evade REDD1-mediated inhibition in a cell line 
dependent manner (Kucejova et al., 2011). Other mechanisms of activation of mTOR 
by HIFs have also been proposed in ccRCC (Elorza et al., 2012). Since DEPTOR is 
an endogenous mTOR inhibitor, one outcome of HIF-mediated suppression of 
DEPTOR in ccRCC could be increased mTOR activity. This was assessed by 
investigating the phosphorylation status of mTOR as well as mTORC1 and mTORC2 
substrates. In line with our previous results, ablation of HIFs either by siRNAs or with 
PT2385 increased DEPTOR accumulation (Figs 4A-4C). The most significant 
change upon inhibition of HIFs was to mTOR phosphorylation directly at ser2448, 
which was notably attenuated. By contrast, mTOR phosphorylation at ser2481 was 
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unaffected. This suggests that HIFs can differentially affect mTOR phosphorylation 
status. To confirm whether DEPTOR directly prevented ser2448 mTOR 
phosphorylation, CRISPR/Cas 9 mediated knockout of DEPTOR was performed in 
VHL competent cells. Loss of DEPTOR increased ser2448 phosphorylation in VHL 
expressing cells (Fig 4D). Together, these results suggest that HIFs have divergent 
effects on mTOR signaling and that HIF-mediated downregulation of DEPTOR in 
ccRCC increases mTOR phosphorylation specifically at ser2448. 
 
Restored expression of DEPTOR inhibits ccRCC tumor colony formation 
Since DEPTOR is an mTOR inhibitor, we hypothesized that its loss in ccRCC would 
increase cell growth and proliferation. To test this, we restored DEPTOR expression 
in ccRCC cells and found that re-expression of DEPTOR inhibited ccRCC growth in 
a colony formation assay (Fig 5A-C). In addition, we used CRISPR/Cas 9 gene 
editing to knockout DEPTOR in VHL competent cells. Consistent with an inhibitory 
role of DEPTOR, its loss resulted in a significant increase in size and number of 
tumor colonies (Fig 5D-F). 
 
DEPTOR controls feedback to IRS-2/PI3K/Akt 
It is established that mTORC1 activates a negative feedback loop to inhibit upstream 
PI3K/Akt signaling thereby regulating its own activity (Rozengurt et al., 2014). 
Previous work has demonstrated that DEPTOR is essential for coordinating the 
proper control of mTORC1 by dampening negative feedback to insulin receptor 
substrate 1 (IRS-1) (Laplante et al., 2012; Peterson et al., 2009). Specifically, the 
mTORC1 substrate, S6K1 phosphorylates IRS-1 at S636/639 to promote its 
degradation, which in turn, reduces PI3K/Akt signaling. As an mTORC1 inhibitor, 
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DEPTOR alleviates this negative feedback loop. Therefore, when DEPTOR is 
manipulated in cells, its overexpression can result in increased Akt phosphorylation 
by dampening negative feedback. Conversely, knock down of DEPTOR reduces Akt 
phosphorylation as mTORC1 is active and negative feedback is predominant (Caron 
et al., 2018; Laplante et al., 2012; Peterson et al., 2009). These effects of DEPTOR 
on mTORC1 feedback seem to override its other function as an mTORC2 complex 
member and negative regulator (Peterson et al., 2009). We confirmed that DEPTOR 
affects Akt phosphorylation at S473 by generating CRISPR/Cas 9 mediated 
DEPTOR knockout in HEK293FT cells (Fig 6A). We then hypothesized that VHL-
defective cells, with chronically suppressed DEPTOR, would have deregulated 
mTORC1 negative feedback signaling to PI3K/Akt. Indeed, 24 h serum deprivation 
led to significantly reduced Akt phosphorylation in RCC4 cells as compared with 
RCC4/VHL cells (Fig 6B). As expected, DEPTOR accumulates upon serum 
starvation in RCC4/VHL cells when HIFs are absent and is degraded upon serum 
stimulation. These results suggest that negative feedback by mTORC1 is amplified 
in VHL-deficient cells as compared with VHL competent cells because VHL-deficient 
cells have lost DEPTOR. We confirmed that DEPTOR was directly regulating 
feedback to Akt by restoring DEPTOR expression in ccRCC cells. Reintroduction of 
DEPTOR to RCC4 and 786-O cells increased phospho Akt without affecting other 
mTORC1 substrates such as phospho S6 ribosomal protein (Fig 6C). Furthermore, 
we show that IRS-2 levels are enhanced in DEPTOR expressing cells (Fig 6D), 
whereas IRS-1 levels were undetectable (data not shown), suggesting that normal 
feedback control to IRS-2/PI3K/Akt is deregulated in ccRCC due to depleted 
DEPTOR levels. 
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DEPTOR loss confers resistance to mTOR kinase inhibition in ccRCC 
Since DEPTOR promotes Akt activity, we predicted that mTOR kinase inhibitors that 
block both mTORC1 and mTORC2/Akt would be more effective in cells that express 
DEPTOR. Consistent with this assumption, reintroduction of DEPTOR in VHL-
deficient ccRCC cells significantly enhanced the efficacy of the mTOR kinase 
inhibitor, AZD2014, to prevent cell proliferation (Fig 7A and 7B). By contrast, 
DEPTOR had no effect on rapamycin treated cells, which predominantly inhibits 
mTORC1 (Fig 7C and 7D). These results demonstrate that loss of DEPTOR is a 
mechanism of resistance specific to mTOR kinase drugs in ccRCC. 
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Discussion 
Here, we show that DEPTOR is significantly downregulated in VHL-deficient ccRCC 
tumors and cell lines and that DEPTOR is transcriptionally suppressed by HIFs. Both 
HIF-1 and HIF-2 negatively regulate DEPTOR, which is mediated by the HIF-target 
gene, BHLHe40. We further show that loss of DEPTOR leads to deregulated 
negative feedback to PI3K/Akt in ccRCC and resistance to second generation mTOR 
kinase inhibitors that block both mTORC1 and mTORC2/Akt. 
 
Low levels of DEPTOR have been found in a number of different tumor types 
(Peterson et al., 2009). However, in some cancers such as multiple myeloma, 
DEPTOR expression is correlated with increased tumor development, likely through 
enhanced PI3K/Akt (Peterson et al., 2009; Wang et al., 2012). In renal tumors, 
mTORC1 pathway activity is elevated in the context of HIF activation. The 
mechanisms of mTORC1 activation are unclear since previous work has 
demonstrated that HIFs negatively regulate mTOR by the HIF-target gene REDD1 
(Brugarolas et al., 2004). However, in renal cancer, mTOR may evade REDD1 
negative regulation and/or mTORC1 may be activated by other HIF-dependent 
mechanisms (Elorza et al., 2012; Kucejova et al., 2011). Our results provide 
evidence that mTOR activity is likely further enhanced by loss of DEPTOR in ccRCC 
in a HIF-dependent manner. This suggests that HIFs have multiple divergent effects 
on mTOR signaling pathways. We clearly show an inhibitory effect of HIFs on 
DEPTOR in ccRCC. This is in contrast to a previous report where hypoxia was 
shown to increase DEPTOR expression in HCT116 cells (Desantis et al., 2015). It is 
possible that the effect of HIFs on DEPTOR may be cell and context specific.  
 
15 
 
We further demonstrate that DEPTOR is repressed by the HIF-target gene, 
BHLHe40 (Fig 8A), which was recently shown to repress PGC-1α in ccRCC (LaGory 
et al., 2015). Our results are consistent with evidence that HIFs downregulate genes 
indirectly and that BHLHe40 plays an important role in negative regulation of HIF 
target genes in ccRCC (Choudhry and Mole, 2016; LaGory et al., 2015).  
 
Through restoration and knockout experiments, we demonstrate that DEPTOR has 
inhibitory effects on tumor cell growth and proliferation in ccRCC in line with previous 
reports in other cancers (Ji et al., 2016; Li et al., 2014; Zhou et al., 2016). It is 
therefore possible that loss of DEPTOR contributes to ccRCC progression. In 
support of this notion, some activating mutations in mTOR in kidney cancer reduce 
binding to DEPTOR (Grabiner et al., 2014), further suggesting that DEPTOR is 
important in negatively regulating mTOR in ccRCC. Evidence shows that DEPTOR is 
critical for coordinated negative feedback signaling to IRS-1/PI3K/Akt (Laplante et 
al., 2012; Peterson et al., 2009). Our results are consistent with these reports, since 
we show that reintroduction of DEPTOR in ccRCC cells increases Akt activity and 
that loss of DEPTOR inhibits Akt signaling. Moreover, we show that IRS-2 levels are 
enhanced in DEPTOR expressing cells suggesting that normal feedback control to 
IRS-2/PI3K/Akt is deregulated in ccRCC due to depleted DEPTOR levels (Fig 8B).  
 
Both intrinsic and acquired drug resistance are the major causes of failure of 
targeted therapy in cancers. In the case of allosteric mTOR inhibitors, such as 
derivatives of rapamycin, acquired resistance occurs from over-activation of 
compensatory feedback loops such as Akt when mTORC1 is inhibited (Rozengurt et 
al., 2014). This phenomenon led to the rationale for the design of second generation 
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mTOR kinase inhibitors that block both mTORC1 and mTORC2, as well as dual 
PI3K/mTOR inhibitors. However, in the case of ccRCC, these compounds are 
inferior to allosteric mTORC1 inhibitors in early clinical trials (Powles et al., 2016a; 
Powles et al., 2016b). The reasons for this are unclear. We reasoned that loss of 
DEPTOR would impact on the efficacy of mTORC1/2 inhibitors, since compensatory 
feedback activation of Akt is diminished in ccRCC cells. We could show that 
reintroduction of DEPTOR in VHL-deficient cells significantly enhanced the efficacy 
of AZD2014 whereas DEPTOR had no effect on the efficacy of rapamycin. Our 
results reveal a novel mechanism of resistance to mTORC1/2 drugs in ccRCC that is 
mediated by HIF-dependent rewiring of mTOR/DEPTOR networks. Importantly, 
these results suggest that restoration of DEPTOR may enhance the efficacy of these 
compounds in ccRCC. 
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Limitations of the study 
This study is focussed on the mechanisms underlying loss of DEPTOR in well 
characterised renal cancer cell lines. In vitro cell colony and proliferation assays 
point to DEPTOR deficiency having a role to play in renal cancer biology and 
resistance to mTOR kinase inhibitors. Data from microarray studies confirm 
DEPTOR is suppressed in renal cancer patients. However, further evidence would 
be required to confirm the role of DEPTOR in ccRCC tumor growth, mTOR 
dysregulation and in response to mTOR inhibitors in vivo to fully clarify the role of 
DEPTOR in renal cancer biology. 
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Figure legends 
Figure 1. DEPTOR is downregulated in VHL-deficient ccRCC tumors and cell 
lines.  
(A) Microarray gene expression analysis of normal kidney samples (n=11), 
hereditary ccRCC tumors (n=32) and spontaneous ccRCC tumors (n=27) extracted 
from data set GSE14994 (Beroukhim et al., 2009). Statistical significance was 
determined by Mann-Whitney non-parametric test. N=normal; T=tumor. 
(B) Microarray gene expression analysis of 10 paired ccRCC tumors and adjacent 
normal kidney extracted from data set GSE6344 (Gumz et al., 2007). Statistical 
significance was determined by Wilcoxon matched-pairs signed rank test. N=normal; 
T=tumor. 
(C) mRNA from VHL-deficient ccRCC cell lines (786-O and RCC4) and cells 
transfected with VHL (786-O/VHL and RCC4/VHL) was analyzed for expression of 
DEPTOR by quantitative real-time PCR (RT-PCR) relative to GAPDH as described 
in Transparent Methods. Data are represented as mean ± SEM. ***p < 0.0001 by 
Student’s two-tailed t test.  
(D) Whole-cell lysates were prepared from ccRCC cell lines (786-O, 786-O/VHL, 
RCC4, RCC4/VHL) and were assayed by immunoblotting as described in 
Transparent Methods. 
The data shown are representative of three independent experiments. 
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Figure 2. DEPTOR is suppressed by HIFs and not mTOR in VHL-deficient 
ccRCC cells. 
(A) VHL-deficient cells (786-O and RCC4) and VHL expressing counterparts (786-
O/VHL and RCC4/VHL) were incubated with increasing concentrations of the 
mTORC1/2 inhibitor, AZD2014, as indicated for 24 h. Whole-cell lysates were 
assessed by immunoblotting for proteins and phosphorylation states as indicated.  
(B) RCC4 and 786-O cells were incubated with the HIF-2 inhibitor, PT2385, for 24 h 
at the concentrations indicated. mRNA expression of DEPTOR was assessed by RT-
PCR relative to GAPDH. Data are represented as mean ± SEM. *p < 0.05; ***p < 
0.0001 by Student’s two-tailed t test.  
(C) RCC4 and 786-O cells were incubated with the HIF-2 inhibitor, PT2385, for 24 h 
and whole-cell lysates were assessed by immunoblotting as described in 
Transparent Methods.  
(D) 786-O cells were treated with siRNA to HIF-2α (H2) or non-silencing control 
(NSC) for 24 h and DEPTOR mRNA assessed by RT-PCR (graph). Data are 
represented as mean ± SEM. Whole-cell lysates were assessed by immunoblotting 
for proteins as indicated (panels).  
(E) RCC4 cells were treated with siRNA to HIF-1α (H1), HIF-2α (H2) or non-silencing 
control (NSC) for 24 h and DEPTOR mRNA was assessed relative to GAPDH by 
RT-PCR. Data are represented as mean ± SEM. *p < 0.05; **p < 0.001 by Student’s 
two-tailed t test.  
(F) RCC4/VHL cells were incubated in normoxia (21% O2) or hypoxia (1% O2) for 24 
h and assayed by immunoblotting. 
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See also Figure S1 and Figure S2. 
 
Figure 3. HIF mediates repression of DEPTOR by BHLHe40. 
(A and B) Microarray gene expression analysis of genes as indicated from matched 
normal kidney (N) (n=10) and ccRCC tumors (T) (n=10), extracted from data set 
GSE6344 (Gumz et al., 2007). Statistical significance was determined by Wilcoxon 
matched-pairs signed rank test. 
(C to E) Correlation of gene expression of genes as indicated in whole data set of 
normal and ccRCC tumors (n=20), extracted from data set GSE6344 (Gumz et al., 
2007). Statistical significance was determined by Pearson’s test. NS=not significant.  
(F) 786-O and 786-O/VHL cells were assessed for BHLHe40 expression. Graph. 
BHLHe40 mRNA levels were determined relative to GAPDH by RT-PCR. Data are 
represented as mean ± SEM. *p < 0.05 by Student’s two-tailed t test. Panels. 
Immunoblotting for proteins as indicated.  
(G) RCC4/VHL cells were incubated in normoxia (N, 21% O2) for 24 h or hypoxia 
(1% O2) for the times indicated and relative mRNA levels of BHLHe40 or DEPTOR 
were determined relative to ribosomal L7 protein by RT-PCR. *p < 0.05 by Student’s 
two-tailed t test.  
(H) 786-O cells were incubated with increasing concentrations of PT2385 as 
indicated and whole-cell lysates were assessed for BHLHe40 protein by 
immunoblotting.  
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(I) Renal cells were treated with siRNA to BHLHe40 or non-silencing control (NSC) 
for 24 h and whole-cell lysates were assessed by immunoblotting for proteins as 
indicated. 
See also Figure S2. 
 
Figure 4. HIF regulates DEPTOR and mTOR phosphorylation at Ser2448 
(A) RCC4 cells were treated with siRNA to HIF-1α (H1), HIF-2α (H2) or non-silencing 
control (NSC) for 24 h and whole-cell lysates were assessed by immunoblotting for 
proteins and phosphorylation states as indicated.  
(B and C) 786-O cells were incubated with increasing concentrations of PT2385 and 
whole-cell lysates were assessed by immunoblotting for proteins and 
phosphorylation states as indicated.  
(D) Immunoblotting of CRISPR/Cas9 mediated knockout of DEPTOR in 786-O/VHL 
cells (sg1 and sg2) or control (sgCtr). 
 
Figure 5. DEPTOR inhibits clonogenic tumor formation in ccRCC. 
(A) Immunoblotting of 786-O FLAG or 786-O FLAG-DEP transduced cells.  
(B) Photomicrograph of clonogenic assay of 786-O FLAG or 786-O FLAG-DEP 
transduced cells following 10 day incubation and stained with crystal violet as 
described in Transparent Methods.  
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(C) Image J quantification of photomicrographs shown in B. Data is represented as 
Mean ± SEM of 4 quadrants. Statistical significance was determined by Student’s 
two-tailed t test. 
(D) Immunoblotting of CRISPR/Cas9 mediated knockout of DEPTOR in RCC4/VHL 
cells (sg1 and sg2) or control (sgCtr).  
(E) Photomicrograph of clonogenic assay of RCC4/VHL cells following 
CRISPR/Cas9 mediated knockout of DEPTOR. Cells were stained with crystal violet 
following 10 day incubation. 
(F) Image J quantification of photomicrographs shown in E. Data is represented as 
Mean ± SEM of 4 quadrants. Statistical significance was determined by Student’s 
two-tailed t test. 
 
Figure 6. DEPTOR controls feedback to IRS-2/PI3K/Akt. 
(A) Immunoblotting of CRISPR/Cas9 mediated knockout of DEPTOR in HEK293FT 
cells (sg1 and sg2) or control (sgCtr).  
(B) RCC4 and RCC4/VHL cells were serum starved for 24 h before re-addition of 
10% serum for 1 or 2 h, as indicated. Whole-cell lysates were assayed by 
immunoblotting. 
(C and D) Immunoblotting of ccRCC control cell lines (RCC4 FLAG and 786-O 
FLAG) or transduced with DEPTOR (RCC4 FLAG-DEP and 786-O FLAG-DEP) for 
proteins and phosphorylation states as indicated. 
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Figure 7. DEPTOR sensitizes ccRCC cells to mTORC1/2 inhibition. 
(A and B) ccRCC control cell lines (RCC4 FLAG and 786-O FLAG) or transduced 
with DEPTOR (RCC4 FLAG-DEP and 786-O FLAG-DEP) were incubated with 
mTORC1/2 kinase inhibitor, AZD2014, at the concentrations indicated for 7 days and 
cell proliferation determined as compared with untreated cells as described in 
Transparent Methods. Data is represented as mean ± SEM of six replicates. 
Statistical significance was determined by Student’s two-tailed t test.  
(C and D) Renal cells as described in (A and B) were treated with 500 nM AZD2014 
(AZD) or increasing concentrations of rapamycin as indicated for 7 days and cell 
proliferation determined as compared with untreated cells. Data is represented as 
mean ± SEM of six replicates. Statistical significance was determined by Student’s 
two-tailed t test. 
The data shown are representative of three independent experiments. 
 
Figure 8. DEPTOR regulates feedback to IRS-2/PI3K/Akt in ccRCC 
(A) Loss or inactivation of VHL function leads to repression of DEPTOR via HIF-
mediated activation of BHLHe40.  
(B) In cells with high DEPTOR levels, mTORC1 is inhibited leading to diminished 
negative feedback to IRS-2/PI3K. This results in enhanced Akt signaling and 
sensitivity to mTOR kinase inhibition. In DEPTOR deficient cells, due to HIF-
mediated repression, mTORC1 activity is enhanced leading to negative feedback to 
IRS-2/PI3K. This results in diminished Akt signaling and resistance to mTOR kinase 
inhibitors.  
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• DEPTOR is suppressed in VHL-inactivated renal cell carcinoma 
• HIF-α mediates DEPTOR suppression via BHLHe40  
• Loss of DEPTOR leads to deregulated mTORC1 negative feedback to IRS-
2/PI3K/Akt 
• DEPTOR loss leads to resistance to mTOR kinase inhibition 








